NEW YORK, July 2, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (NASDAQ: AMLN) concerning the proposed acquisition of the Company by Bristol-Myers Squibb Co. ("Bristol-Myers") in a transaction valued at approximately $5.3 billion.
On July 2, 2012, it was announced that Amylin and Bristol-Myers have entered into a definitive agreement pursuant to which Bristol-Myers will acquire Amylin. Under the agreement, Amylin shareholders will receive $31.00 in cash per share held. The transaction price represents a scant 10% premium over Amylin's June 29, 2012 closing price, and at least one analyst has set a target price for Amylin stock of $32.00 per share.
Our investigation concerns whether the Amylin board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.
If you own Amylin shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin Sachs-Michaels, Esq. Robert I. Harwood, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email:[email protected] Website:http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.